Improving Drug Adherence Among Adolescents in Uganda Using SMS Reminders (RATA)
12 avril 2017 mis à jour par: Sebastian Linnemayr, RAND
In this project the investigators develop and test a short message service (SMS) intervention based on the Information Motivation and Behavior skills (IMB) model.
Reminding Adolescents To Adhere (RATA) prompts youths at two clinics in Uganda to take their medications and offers social support via weekly text messages.
The investigators propose to adapt their previous successful SMS-intervention to the specific needs of youths and to evaluate the relative effectiveness of one-way versus two-way text messages (where two-way messages allow youths to respond to messages and we hypothesize that this may increase perceived social support that may be important for youth populations).
We will also test the effectiveness of SMS messages over the longer-term (2 years), for which currently no information is available.
Aperçu de l'étude
Statut
Complété
Les conditions
Intervention / Traitement
Description détaillée
The primary goal of the proposed study is to develop and test SMS-based text messages for improving medication adherence among HIV-positive youths in a resource-limited setting.
The study will be conducted in three phases: Phase 1 will consist of qualitative interviews with patients, clinic providers and directors, and community leaders and will elicit information on barriers to treatment and adherence patterns and cognitive obstacles to adherence that may be addressed by RATA.
A second focus of this phase will be to investigate the familiarity with and attitude towards SMS messages among adolescents, and their attitudes towards different aspects of these messages.
Parameters of the messages that will be probed include their frequency, content, and form using Figure 1 as a guiding principle for this exploratory phase.
Phase 2 will use the findings from Phase 1 to develop and implement RATA in a randomized controlled trial (RCT).
A sample of 330 clients aged 15-24 who are in HIV care and show signs of problems with adherence will be recruited and randomized into one of three equal-sized intervention arms: a control group that will receive usual care, or one of two treatment groups in which participants will receive usual care and additionally will receive either two-way SMS messages or one-way SMS messages.
All RATA participants will be followed for two years.
Assessments will be conducted at baseline and every 6 months over the course of 24 months.
Medication event monitoring system (MEMS)-caps measured medication adherence will be the primary outcome measure, while viral load (for a subset of clients) CD4 count, self-reported adherence and pharmacy refill data as well as retention in care constitute secondary outcomes.
Phase 3 will be used to analyze the collected data, conduct qualitative interviews with providers, clinic administrators, and study participants to learn about implementation difficulties and areas of improvement, and to share preliminary results and project implementation insights with these key players.
This stage allows evaluating the feasibility and sustainability of the intervention for potential scale-up, for which we will also conduct a relative cost-effectiveness analysis of two- versus one-way messages.
RATA will be extended to the control group in Year 5 if findings from phase 2 suggest its success at improving outcomes.
Type d'étude
Interventionnel
Inscription (Anticipé)
330
Phase
- N'est pas applicable
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Lieux d'étude
-
-
-
Kampala, Ouganda
- Infectious Diseases Institute
-
Kampala, Ouganda
- Mildmay Uganda
-
-
-
-
California
-
Santa Monica, California, États-Unis, 90407
- RAND
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
15 ans à 24 ans (Enfant, Adulte)
Accepte les volontaires sains
Non
Sexes éligibles pour l'étude
Tout
La description
Inclusion Criteria:
- age 15-24
- have been in HIV care at the clinic for at least three months
- are currently taking HIV-related medication (ART or co-trimoxazole)
- have demonstrated adherence problems (defined as having missed at least one medication dose per week on average)
- either own a phone or have regular access to one
- intend to stay at the clinic for the study period
- are not in boarding school (where phones are forbidden)
Exclusion Criteria:
- does not speak or understand either English or Luganda
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Recherche sur les services de santé
- Répartition: Randomisé
- Modèle interventionnel: Affectation factorielle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Aucune intervention: Control group
This study arm will receive care as usual.
|
|
|
Expérimental: Two-way SMS intervention group
Two-way messages allow the recipient of the SMS message (the patient) to respond to the messages ("We hope you are feeling well today.
Reply 1 if well, 2 if unwell") to request a follow-up call from the clinic.
|
Clients will receive a weekly two-way SMS, meaning that the clients in this group will receive the same message as in the one-way SMS study arm, but in addition will be asked how they feel.
Clients are required to either press 1 or respond "well" or press 2 or write 'Unwell" in response in the language of their choice within 48 hours.
A missing response after 48 hours triggers a second SMS to remind the client to respond.
If after 24 more hours the participant still does not respond or if at any point s/he responds "unwell" then the study coordinator will follow up with a call within 24 hours.
|
|
Expérimental: One-way SMS intervention group
Clients will receive a weekly one-way SMS with the message "We hope you are feeling well today."
There will be no prompt for response.
|
Clients will receive a weekly one-way SMS message.
There will be no prompt for any response.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Medication adherence rates using electronically monitored adherence (MEMS cap) data
Délai: 6 months after enrollment
|
Medication Event Monitoring System (MEMS)-cap data will be collected continuously over the course of the 24-month study period allowing us to investigate daily adherence and its timing.
MEMS caps data indicating the date and time when the participant opened their pill bottle (either one of the ART medications or prophylaxis if not on ART yet) will be used to calculate the primary outcome variable of adherence (# of actual bottle openings / # of prescribed bottle openings).
|
6 months after enrollment
|
|
Medication adherence rates using electronically monitored adherence (MEMS cap) data
Délai: 12 months after enrollment
|
Medication Event Monitoring System (MEMS)-cap data will be collected continuously over the course of the 24-month study period allowing us to investigate daily adherence and its timing.
MEMS caps data indicating the date and time when the participant opened their pill bottle (either one of the ART medications or prophylaxis if not on ART yet) will be used to calculate the primary outcome variable of adherence (# of actual bottle openings / # of prescribed bottle openings).
|
12 months after enrollment
|
|
Medication adherence rates using electronically monitored adherence (MEMS cap) data
Délai: 24 months after enrollment
|
Medication Event Monitoring System (MEMS)-cap data will be collected continuously over the course of the 24-month study period allowing us to investigate daily adherence and its timing.
MEMS caps data indicating the date and time when the participant opened their pill bottle (either one of the ART medications or prophylaxis if not on ART yet) will be used to calculate the primary outcome variable of adherence (# of actual bottle openings / # of prescribed bottle openings).
|
24 months after enrollment
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Fraction of clients displaying adherence of 90% or more
Délai: At 6, 12, 18 and 24 months
|
MEMS caps data indicating the date and time when the participant opened their pill bottle (either one of the ART medications or prophylaxis if not on ART yet) will be used to calculate the secondary outcome measures of fraction of clients displaying adherence of 90% or more.
|
At 6, 12, 18 and 24 months
|
|
Indicator for treatment interruptions of more than 48 hours
Délai: At 6, 12, 18 and 24 months
|
MEMS caps data indicating the date and time when the participant opened their pill bottle (either one of the ART medications or prophylaxis if not on ART yet) will be used to calculate the secondary outcome measures of an indicator for treatment interruptions of more than 48 hours.
|
At 6, 12, 18 and 24 months
|
|
Viral load assays
Délai: At month 12
|
A randomized subset of 30 clients from each intervention arm (90 total) will measure viral load assays at month 12.
|
At month 12
|
|
Self-reported adherence
Délai: At baseline, 6, 12, 18 and 24 months
|
We will ask about number of missed doses over the past 7 days.
Adherence is calculated as a proportion of prescribed doses taken.
|
At baseline, 6, 12, 18 and 24 months
|
|
Pharmacy Refill Adherence
Délai: Months 6, 12, 18 and 24
|
All patients on ART receive their medications in 30-day supplies from the Infectious Disease Institute (IDI) and Mildmay clinic pharmacies.
For clients on co-trimoxazole, the drugs are typically dispensed in units of 90 count.
We will adjust the measure according to the refill period specific to each client.
A composite continuous multiple interval measure of medication availability or refill rate will be calculated (# of pills dispensed/ # pills prescribed per day)/ days between refills.
|
Months 6, 12, 18 and 24
|
|
Clinic Attendance
Délai: Continuous over 24 months
|
Attendance at regularly scheduled clinic visits as part of usual care will be tracked for all participants from the electronic client database and will be available in real-time to the study coordinator.
|
Continuous over 24 months
|
|
Cluster of differentiation 4 (CD4) count
Délai: Occasionally over 24 months
|
CD4 counts will be chart abstracted from the clinic data; they are typically taken about every six months
|
Occasionally over 24 months
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Parrainer
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude
1 février 2013
Achèvement primaire (Réel)
31 janvier 2016
Achèvement de l'étude (Réel)
31 mars 2017
Dates d'inscription aux études
Première soumission
15 avril 2014
Première soumission répondant aux critères de contrôle qualité
29 avril 2014
Première publication (Estimation)
1 mai 2014
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
14 avril 2017
Dernière mise à jour soumise répondant aux critères de contrôle qualité
12 avril 2017
Dernière vérification
1 avril 2017
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Infections par virus à ARN
- Maladies virales
- Infections
- Infections transmissibles par le sang
- Maladies transmissibles
- Maladies sexuellement transmissibles, virales
- Maladies sexuellement transmissibles
- Infections à lentivirus
- Infections à rétroviridae
- Syndromes d'immunodéficience
- Maladies du système immunitaire
- Maladies à virus lents
- Infections à VIH
- Syndrome immunodéficitaire acquis
Autres numéros d'identification d'étude
- 1R01HD074925-01 (Subvention/contrat des NIH des États-Unis)
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .